MKI67 and neoplasm: A reduction in serum TK1 activity by palbociclib had a sensitivity of 94.1% (32 of 34, 95% CI 86.2% -100%) and a specificity of 84% (21 of 25, 95% CI 69.6% -98.4%) in predicting tumor Ki-67 response in this patient population.